Skip to main content
Ovarian Cancer
Combination Therapy May Improve Outcomes for Patients with Ovarian Cancer
Read More
Ovarian Cancer
State and Federal Legislation Addresses PBM Pricing Transparency
Read More
Ovarian Cancer, PARP Inhibitors
Proper Management of Toxicities Associated with PARP Inhibitors Is Essential for Optimizing Treatment Outcomes
Read More
Lung Cancer, Thyroid Cancer, FDA Updates
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Read More
Sarcoma, FDA Updates
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Read More
Ovarian Cancer
PARP Inhibitor Use in Ovarian Cancer Expands Beyond Treatment for Recurrent Disease
Read More
Ovarian Cancer
Final Rule Regarding Copay Accumulator Programs May Increase Patients’ Out-of-Pocket Costs for Oral Cancer Drugs
Read More
Ovarian Cancer
Medicare Proposes Legislative Changes to Protected Drug Classes, Including Antineoplastics
Read More
Ovarian Cancer
Federal Oral Parity Legislation for Anticancer Drugs Awaits Action from Senate
Read More
Ovarian Cancer
Understanding Medicare Part D Prescription Drug Coverage Changes for 2020
Read More
Page 141 of 196
Results 1401 - 1410 of 1954